Treating NF2 Inactive Mutation in Meningiomas

Abstract

Meningioma is the most prevalent adult brain tumor with frequent somatic deletion of neurofibromatosis 2 (NF2). NF2 mutation in meningiomas tend to be relapsed which is limited in treatment option. Thus, personalized treatment for these circumstances are essential. The purpose of this literature review describes how the current development of NF2 mutation treatment approach in meningiomas. Targeting mTOR signaling using MLN3651 combine with selumetinib is one of a potential option for NF2 inactivation meningiomas. A novel therapeutic approach by inhibit EPH receptor signaling. There was also another option to treat NF2 meningiomas using demethylation drugs.